Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB-11
- Development stage
- Approved
- Lead developer
- Samsung Bioepis
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
SB-11 is a biosimilar of ranibizumab, developed by Samsung Bioepsis. It is currently in development for the treatment of neovascular age-related macular degeneration (AMD). As a biosimilar to ranibizumab, its therapeutic action is based on inhibiting vascular endothelial growth factor A (VEGF-A), a key mediator in the development of choroidal neovascularization, which is characteristic of wet AMD.
- Brand names
- Byooviz
- Other names
- ranibizumab-nunaSB11 PFSSB-11 PFSSB 11 PFS
02
Targets
Beyond the preview
Go deeper on SB-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB-11.